【摘要】 目的评价达肝素在冠脉支架植入术中抗凝的安全性和有效性。方法拟入选300例择期冠脉造影手术后行支架置入术患者,随机分UFH组、达肝素60IU组和达肝素80IU组三个组。收集患者入院时以及冠脉支架置入术后30 d临床资料。达肝素组患者抗凝药注入前、抗凝药注入后5 min、15 min、30 min、1 h、2 h、3 h、4 h监测抗Xa因子活性。结果前50例入组患者中,29例患者随机分到低分子肝素组,其中13例60IU/KG达肝素组入选患者中,3例患者出现术中冠脉内血栓,发生率为23.08%,实验终止,重新设计实验。结论冠脉介入术中60IU/KG剂量的达肝素存在抗凝不足的问题,特别是在复杂冠脉病变的冠脉介入术中。更多还原

【Abstract】 To evaluate the safety and effectiveness of dalteparin in patients with complex coronary lesions in interventional anticoagulation. Methods A total of 300 patients were divided into 3 groups: UFH group,60 IU dalteparin group and 80 IU dalteparin group. Clinical data of patients’ admission and 30 days after coronary stent were collected. All patients were followed up and the data were recorded. Anti-Xa factor activity levels of pre-operation,5min,15 min,30min,1h,2h,3h and 4h after dalteparin infusion were tested. Results There were 3( 23. 08%) patients had thrombus formation events in 60 IU dalteparin group. When the experiment was terminated,program was designed again. Conclusions 60 IU dalteparin programme in patients with complex coronary lesions in interventional anticoagulation is not safe enough.更多还原